The Effect of \u3cem\u3eACP1-ADA1\u3c/em\u3e Genetic Interaction on Human Life Span by Lucarini, Nazzareno et al.
Wayne State University
Human Biology Open Access Pre-Prints WSU Press
9-1-2012
The Effect of ACP1-ADA1Genetic Interaction on
Human Life Span
Nazzareno Lucarini
Laboratory of Human Genetics, School of Biosciences and Biotechnology, Via Gentile III da Varano, University of Camerino,
62032 Camerino, Italy
Valerio Napolioni
Laboratory of Human Genetics, School of Biosciences and Biotechnology, Via Gentile III da Varano, University of Camerino,
62032 Camerino, Italy
Andrea Magrini
Department of Biomedicine and Prevention, Via Montpellier, University of Rome Tor Vergata, 00133 Rome, Italy
Fulvia Gloria
Department of Biomedicine and Prevention, Via Montpellier, University of Rome Tor Vergata, 00133 Rome, Italy
This Open Access Preprint is brought to you for free and open access by the WSU Press at DigitalCommons@WayneState. It has been accepted for
inclusion in Human Biology Open Access Pre-Prints by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Open access pre-print, subsequently published as Lucarini, N, Napolioni, V, Magrini, A, and Gloria, F. (2012). "The Effect of ACP1-




The Effect of ACP1-ADA1 Genetic Interaction on Human Life Span 
Nazzareno Lucarini1*, Valerio Napolioni1*, Andrea Magrini2 , and Fulvia Gloria2 
 
1Laboratory of Human Genetics, School of Biosciences and Biotechnology, Via Gentile III da 
Varano, University of Camerino, 62032 Camerino, Italy 
2 Department of Biomedicine and Prevention, Via Montpellier, University of Rome Tor Vergata, 
00133 Rome, Italy 
 






Running title: ACP1-ADA1 interaction and life-span 
 
KEY WORDS: ACP1, ADA1, LONGEVITY, GENETIC INTERACTION, SIRTUIN GENES 
 
 
Pre-print version. Visit 
http://digitalcommons.wayne.edu/humbiol/ 




Acid phosphatase (ACP1) is a polymorphic enzyme which catalyzes the conversion of flavin-
mononucleotide (FMN) to riboflavin and regulates the cellular concentration of flavin-adenine-
dinucleotide (FAD) and, consequently, energy metabolism. Its activity is modulated by 
adenosine deaminase (ADA1) genotype. Aim of our work is to verify whether individuals with a 
high proportion of ACP1 f isozyme and carrying ADA*2 allele, displaying the highest 
phosphatase activity, may have a higher life expectancy. 
Genomic DNA was extracted from peripheral blood of 569 females and 509 males (18-106 
years) randomly recruited from Central Italy. These samples were subdivided into three sex-
specific age groups (the ages of  women are in square bracket): Class 1:age <66 [<73]; Class 2: 
age 66-88 [73-91]; Class 3: age >88 [>91]. ACP1and ADA1 SNPs were genotyped by RFLP-PCR 
methods and statistical analyses were performed using SPSS 14.0. The results showed a larger 
proportion of Class 3 individuals displaying high ACP1 f isozyme concentration and carrying 
ADA1*2 allele than those of Class 2 and Class 2+1. Thus, we postulate that in Class 3 individuals 
the high phosphatase activity, resulting from the combined presence of high ACP1 f isozyme 
concentration and the ADA1*2 allele, lowers the rate of glycolysis which may reduce the amount 
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ACP1 gene (gene map locus 2p25) encodes for the ACP1 polymorphic enzyme also called 
Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP). Two functions have been 
suggested for ACP1: flavin-mononucleotide (FMN) phosphatase and tyrosine phosphatase. As 
flavin–mononucleotide phosphatase, ACP1 catalyzes the conversion of FMN to riboflavin, thus 
regulating cellular flavin-adenine-dinucleotide (FAD) concentration, flavo-enzyme activity and 
energy metabolism. As phosphotyrosine phosphatase, ACP1 may modulate the glycolytic rate 
controlling insulin receptor activities and band 3 protein status.  
ACP1 shows three common codominant alleles, ACP1*A, ACP1*B and ACP1*C, whose 
combinations define six phenotypes characterized by different enzyme activity (in the order, 
A<B/A<(B, C/A)<C/B). The ACP1 C phenotype is very rare being present only in Caucasian people 
and it displays the highest enzyme activity (Boivin and Galand 1986; Bottini et al. 2002; Fuchs et 
al. 1992; Spencer et al. 1964).  
  Low ACP1 activity makes an individual more susceptible to allergic disorders, to Th1-
immune diseases, to type 1 diabetes and Crohn’s disease, and lowers the age at onset (≤ 6yr) of type 
1 diabetes. ACP1 *A/*A and *B/*A genotypes are over-represented in children with idiopathic 
generalized tonic-clonic seizures, suggesting a detrimental role of low ACP1 activity also in central 
nervous system. ACP1*A allele has the highest frequencies in the population of northern latitudes 
and it has been associated with greater body size and with adaptation to cold stress. ACP1 A and 
ACP1 B/A phenotypes are also associated with severe body mass increase in obese adult subjects, in 
obese diabetic pregnant women and in normal children (Bottini et al. 1990; Bottini et al. 2002a; 
Bottini et al. 2002b; Bottini et al. 2007; Gloria-Bottini et al. 2007; Greene et al. 2000; Lucarini et al. 
1990; Paggi et al. 1991). 
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The ACP1 gene expresses two isozymes (f and s) showing different concentrations among 
the six ACP1 phenotypes. These isozymes are expressed simultaneously in many tissues and they 
are characterized by different biological functions. ACP1 f isozyme is the main responsible of the 
total ACP1 activity (Dissing and Svensmark 1990; Fujimoto et al. 1988; Stefani et al. 1993). Since 
different effects on f and s isozymes activity result from modulation of ACP1 enzymatic activity, C, 
CA and A phenotypes - characterized by lower concentrations of f isozymes - could be more 
susceptible to damage by oxidative events compared to the other phenotypes. Notably, leiomyoma 
size is negatively correlated with ACP1 f isozyme concentrations regulating negatively cell 
proliferation and growth of leiomyomas through dephosphorylation of the PDGF receptor 
(Ammendola 2009). 
Adenosine deaminase locus 1 (ADA1) is a polymorphic enzyme catalyzing the irreversible 
deamination of adenosine to inosine. It is present in all mammalian tissues and it is controlled by a 
locus on the long arm of chromosome 20 with two co-dominant alleles ADA1*1 and ADA1*2 having 
different associated enzymatic activities. ADA1*1 allele displays 30% higher enzymatic activity 
than ADA1*2 allele (Battistuzzi et al. 1974). Experimental studies have also shown that adenosine, 
acting via adenosine 1 receptor, increases insulin sensitivity in isolated adipocytes and decreases 
insulin sensitivity in isolated muscle fibers (Challis et al. 1992; Dunwiddie and Masino 2001; 
Vannucci et al. 1992 ). Interest has been focused on a wide variety of effects produced by adenosine 
through the activation of cell surface adenosine receptors (Richardson 1997; Xu et al. 1998; Yasuda 
et al. 2003). Transient activation of adenosine receptors protects against damage following hypoxic 
or ischemic events in brain and in other excitable tissues such as heart. Variation in energy states, 
cardiac stress or other stimuli induce the release of adenosine which by its receptors can lead to a 
more efficient balance between energy utilization and energy supply, also protecting cardiac cells 
under extreme stress conditions (Headrick et al. 2011). 
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ACP1 enzyme activity is modulated by ADA1 genotype: in carriers of ADA1*2 allele, 
ACP1 A, BA, CA and CB activity is lower than in homozygous for ADA1*1 allele (Lucarini et al. 
1989). A positive association of the genotype ACP1*A/*A and ADA1*2 allele with type 1 
diabetes and a negative correlation between the frequency of this gametic type with past malarial 
morbidity in Sardinia (Gloria-Bottini et al. 2010) have been already reported. Moreover, a 
significant association between ACP1 and ADA1 has been found in Caucasians living in 
Australia and in a Brazil (Engràcia et al. 1991)  
Since ACP1 f isozyme is the main responsible of ACP1 activity modulated by ADA1 we 
tested whether the subjects with a high proportion of ACP1 f isozyme and carrying ADA1*2 allele 
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Materials and Methods 
Subjects 
Peripheral blood was obtained from 1072 (569 females and 503 males) unrelated 
individuals, 18–106 years old, randomly recruited from the same geographical area of Central 
Italy (Marche region) on the eastern side of the Apennines. The whole population studied was 
composed by Caucasian individuals all descendants of an ancient pre-Roman Italian population 
called the Piceni (Cavalli-Sforza et al. 1994). The same donors provided information concerning 
their health condition. No  pathological condition existed (e.g. cancer, diabetes, heart diseases, 
hypertension, obesity, and chronic inflammatory diseases). The sample study was divided into 
three sex-specific age classes ( the age classes of women are written in square bracket)  The first 
age class was made by men with age <66  [<73], the second class by men  with age 66-88  [73-
91], and the third class by men with an age  >88  [>91]. These gender-specific age classes were 
defined according to demographic information and accounted for different survivals of men and 
women in Italian population (Passarino et al. 2006). The study protocol was approved by the 
Joint Ethical Committee (JEC) University of Camerino-Azienda ASUR Marche ZT-10 
Camerino, in accordance with the Declaration of Helsinki in its revised edition and with 
international and local regulatory requirements. 
 
Genotyping 
Genomic DNA extraction was carried out from peripheral blood through standardized 
salting out method and DNA was stored at −20 °C until gene analysis.  
ACP1 and ADA1 SNPs were genotyped according to RFLP-PCR methods previously 
published (Lazaruk 1995; Napolioni and Lucarini 2010). For ACP1, all PCRs were set up in 30 
µl and 0.2 µmol/L of both primers, 0.1 mmol/L dNTPs, 1.5 mmol/L MgCl2, 0.5 U of Taq 
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polymerase (AmpliTaq, Applied Biosystem, Mannheim, Germany), 1X AmpliTaq buffer (PE), 
and 50 ng of DNA template. The amplification conditions consisted of an initial denaturation at 
94°C for 2 minutes, followed by 35 cycles of 94°C for 45 seconds, 54°C for 45 seconds, 72°C 
for 45 seconds, and a final extension at 72°C for 5 minutes. The annealing temperature, 
extension time, and primer concentration for the 2-kb amplification product were 57°C, 120 
seconds, and 0.1 µmol/L, respectively. Oligonucleotides used for PCR amplification are reported 
in Table 1. The C>T transition at codon 43 and the A>G transition at codon 105 generate a CfoI 
and a TaqI restriction site that, together, were used for PCR-based genotyping, respectively. A 
341-bp segment spanning the entire exons 3 and 4 was amplified using primers 263 to 264 
(Table 1). A 299-bp segment including exon 6 was amplified using primers 267 and 268. Ten 
microliters of the 341-bp exon 3 amplicon was fully cleaved by CfoI  at 37°C for 1 hour 
according to the manufacturer’s instructions and then electrophoresed on 1.8% agarose gels. The 
digestion created two fragments of 255 and 86 bp for the ACP1*A and ACP1*B haplotype, 
whereas the ACP1*C haplotype was not cut. Similarly, the 299-bp PCR product was digested by 
TaqI at 65°C for 1 hour according to the manufacturer’s instructions, generating 2 fragments of 
100 and 199 bp for the ACP1*A haplotype but not for the *B and *C haplotypes. 
Briefly, for ADA1, PCR was performed with primers flanking the 22G>A polymorphic region: 
5’-GCCCGGCCCGTTAAGAAGAGC-3’ as sense primer, and 5’-
GGTCAAGTCAGGGGCAGAAGCAGA-3’ as antisense primer. The PCR products were 
digested with TaqI endonuclease for 90 min at 65°C, and the samples were electrophoresed in a 




Haplotype and genotype frequency were calculated by genotype counting method. 
Hardy–Weinberg Equilibrium (HWE) was assessed by comparing the genotype frequencies with 
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the expected values using a contingency table χ 2 statistics. Means and T-test for difference 
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Table 2 shows the frequency of ACP1 genotypes in relation to ADA1 genotypes and 
classes of age in males and females separately. All age classes are in Hardy-Weinberg 
Equilibrium. In both sexes ACP1 *A/*B and *B/*B – ADA1 genotypes have a greater frequency 
in all age classes. 
Table 3 shows f and s ACP1 genotype isozyme concentrations according to Dissing 
(Dissing 1987, 1993). The data of Dissing are reported to clarify the procedure to obtain the data 
reported in Table 4. 
Table 4 shows the concentration of ACP1 f isozyme - ADA1*2 allele along the three age 
classes studied. The mean value of ACP1 f isozyme amount among the various ACP1-ADA1*2 
genotypes is reported for each class (Dissing 1987, 1993). It is also reported the T test for 
differences between means. The concentration of ACP1 f  isozyme - ADA1*2 allele  in Class 3 
subjects is higher than the one in Class 2 and Class 1, but, compared to the Class 1, it does not 
reach statistical significance (p=0.053). ACP1 f isozyme - ADA1*2 allele concentration of 
subjects in Class 1 is not different from that of subjects in Class 2 while the differences between 
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In Class 3 compared to Class 2, or to Class 2 plus Class 1, there is a significant excess of 
individuals displaying higher amount of ACP1 f isozyme – ADA1 *2 allele (table 4). Boivin and 
Galand (1986) demonstrated that ACP1 dephosphorylates the tyrosine residues of the erythrocyte 
membrane protein 3 (B3P). The phosphorylation of B3P tyrosines prevents the binding of several 
glycolytic enzymes, causing high glycolytic rates in erytrocytes (Harrison et al. 1991; Low et al. 
1987). Furthermore, Stefani et al. (1993) demonstrated that the phosphotyrosine of a syntethic 
peptide corresponding to the sequence 5-16 of the B3P is much more efficiently hydrolyzed by the 
ACP1 f isozyme than s isozyme. Therefore, as the ACP1 f amount is strongly related to ACP1 
activity (Dissing and Svensmark 1990; Stefani et al. 1993) and its activity is enhanced by ADA1*2 
(Lucarini et al. 1989), it is conceivable that this fact may result in a significantly dephosphorylation 
of tyrosine residue of B3P, slowing glycolytic rates in erythrocytes. Therefore, this may affect the 
Krebs cycle resulting in a lesser amount of metabolic calorie. Moreover, the highest ACP1 activity 
can dephosphorylate insulin receptor, counteracting the action of insulin and decreasing glucose 
utilization.  
Calorie restriction in mammals activate the Sirtuin genes (Baur et al. 2010; Bordone and 
Guarente 2005; Civitarese et al. 2007; Cohen et al. 2004; Imai and Guarente 2010; Kelly 2010; Qiu 
et al. 2010) which protect cells against age-related diseases such as, cancer, atherosclerosis, 
cardiovascular diseases, neurological disorders and diabetes (Haigis and Guarente 2006; Haigis and 
Sinclair 2010; Kim and Um 2008; Kim et al. 2007; Lagouge et al. 2006; Milne et al. 2007; 
Westphal et al. 2007). We suggest that subjects displaying higher amount of ACP1  f isozyme and 
carrying ADA1*2 allele probably display a higher life-expectancy for a lower amount of metabolic 
calories. Moreover, higher concentration of both circulating and intra-cellular adenosine (Battistuzzi 
et al. 1974) can enjoy positive effects on neural and cardiac tissues during hypoxic or ischaemic 
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events (Cohen and Downey 2008; Headrick et al. 2011; Latini and Pedata 2001; Mubagwa and 
Flameng 2001; Peaeson et al 2003; Pedata et al. 2007). 
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Table 1. Primers used for ACP1 SNPs analysis 
 
Primer Target Amplification Nucleotide Sequence 5’-3’ 
#263 Exon 3 AGGCCACCTGAACTCCTCT 
#264 Exon 3 CCTGTCTTGTTTATGGGCT 
#267 Exon 6 TTCAGAAGACCCTAGCAGATG 
#268 Exon 6 TGGCAAAACCTGCATAACAA 
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Table 2. Distribution of ACP1 genotype in relation to ADA1  and classes of age in females and males 
 
  ADA1 *1/*1 ADA1 *2 carriers 
Sex ACP1 Age Classes Age Classes  
  1 2 3 1 2 3 
Females *A/*A 4.8% 14.7% 7.2% 7.0% 11.4% --- 
 *B/*A 47.3% 41.5% 42.2% 34.9% 34.1% 41.2% 
 *B/*B 41.1% 41.9% 41.0% 44.2% 43.2% 52.9% 
 *C/*A 2.1% 2.5% 2.4% 7.0% 4.5% --- 
 *C/*B 4.8% 9.3% 7.2% 7.0% 6.8% 5.9% 
 *C/*C --- --- --- --- --- --- 
Total n°  146 236 83 43 44 17 
ACP1 Hardy-Weinberg Equilibrium (p) Class 1  0.226; Class 2  0.325; Class 3  0.730   
ADA1 Hardy-Weinberg Equilibrium (p) Class 1  0.270; Class 2  0.513; Class 3  0.845   
 
Males *A/*A 6.3% 5.8% 6.5% --- 11.8% --- 
 *B/*A 38.3% 35.6% 37.0% 50.0% 41.2% 25.0% 
 *B/*B 43.0% 43.3% 42.4% 37.5% 41.2% 75.0% 
 *C/*A 6.3% 6.7% 3.3% 6.3% 3.9% --- 
 *C/*B 4.7% 8.7% 10.9% 6.3% 2.0% --- 
 *C/*C 1.6% --- --- --- --- --- 
Total n°  128 208 92 16 51 8 
ACP1 Hardy-Weinberg Equilibrium (p) Class 1  0.057; Class 2  0.115; Class 3  0.936   
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Table 3. f and s isozyme concentrations in relation to ACP1 genotype (as reported in Dissing  1987, 1993). 



























Total quantity of f (µg/mL 
RBC) 
Total quantity of s (µg/mL 
RBC) 
    *B/*B 16.4      *C/*C 20.6 
     *B/*A 12.0      *C/*A 12.7 
     *C/*B 11.3      *C/*B 12.1 
     *A/*A  7.9      *B/*B  3.9 
     *C/*A  7.5      *B/*A  3.4 
     *C/*C  5.7      *A/*A  3.3 
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Table 4.  Concentration of ACP1 f isozyme-ADA1*2 allele in relation to age classes 
 
 
 ACP1 f isozyme-ADA1*2 allele 
Age classes Mean S.D. S.E. Total n° 
Class 1 13.3 2.99 0.39 59 
Class 2 13.16 3.12 0.32 95 
Class 3 14.61 2.24 0.45 25 
T-test for differences between means (p) 
Class 2 vs. Class 1                      0.777 
Class 3 vs. Class 1                      0.053 
Class 3 vs. Class 2                      0.031 
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